2012
DOI: 10.1167/iovs.11-8544
|View full text |Cite
|
Sign up to set email alerts
|

TUDCA Slows Retinal Degeneration in Two Different Mouse Models of Retinitis Pigmentosa and Prevents Obesity in Bardet-Biedl Syndrome Type 1 Mice

Abstract: TUDCA treatment preserved ERG b-waves and the outer nuclear layer in Bbs1(M390R/M390R) mice, and prevented obesity assessed at P120. TUDCA treatment preserved ERG b-waves and the outer nuclear layer in the rd10 mice to P30. TUDCA is a prime candidate for treatment of humans with retinal degeneration, especially those with Bardet-Biedl syndrome, whom it may help not only with the vision loss, but with the debilitating obesity as well.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
75
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 84 publications
(75 citation statements)
references
References 37 publications
0
75
0
Order By: Relevance
“…In addition, we show that in genetically normal rod photoreceptors there is bystander cell death mediated through a caspase-dependent mechanism. Our data may provide an explanation of why using single inhibitors of cell death have had limited rescue effects and poor longterm outcomes when tested in other retinal degeneration models, 36,37 because the rod and cone photoreceptors are dying by different mechanisms so eventually all the photoreceptors are lost. The significance of our findings is that combination therapy directed at the different cell death mechanisms would be crucial in designing effective treatment strategies.…”
Section: Discussionmentioning
confidence: 93%
“…In addition, we show that in genetically normal rod photoreceptors there is bystander cell death mediated through a caspase-dependent mechanism. Our data may provide an explanation of why using single inhibitors of cell death have had limited rescue effects and poor longterm outcomes when tested in other retinal degeneration models, 36,37 because the rod and cone photoreceptors are dying by different mechanisms so eventually all the photoreceptors are lost. The significance of our findings is that combination therapy directed at the different cell death mechanisms would be crucial in designing effective treatment strategies.…”
Section: Discussionmentioning
confidence: 93%
“…Synthetic TUDCA has been shown to exhibit antiapoptotic properties in neurodegenerative diseases, including those affecting the retina. Systemic administration of TUDCA has been demonstrated to slow retinal degeneration in both the rd10 autosomal recessive RP mouse model (Boatright et al, 2006;Drack et al, 2012;Oveson et al, 2011;Phillips et al, 2008) and in a LIRD mouse model (Boatright et al, 2006;Oveson et al, 2011). In these two retinal degeneration models, TUDCA-treated animals were shown to maintain better visual function, thicker ONL and better preservation of outer segments than untreated animals.…”
Section: Tauroursodeoxycholic Acid (Tudca)mentioning
confidence: 99%
“…21 Tauroursodeoxycholic acid also rescued ERG b-waves and the outer nuclear layer in an animal model of retinal degeneration. 31 The dosage used in most in vitro experiments is much lower; for example, 100 lM of TUDCA added to culture medium effectively protected retinal neural cell cultures from cell death induced by elevated glucose concentration, decreased the mito-nuclear translocation of apoptosis-inducing factor, 32 and suppressed expression of p-c-Jun and p-JNK in diabetic rat retinas and retinas exposed to high glucose. 33 However, little is known about the dosage and direct effects of TUDCA on the visual response properties of RGCs under excessive oxidative stress.…”
Section: Tudca Impact On Retinal Neurocircuitrymentioning
confidence: 99%